GT Biopharma (GTBP) Retained Earnings (2016 - 2021)
GT Biopharma (GTBP) has disclosed Retained Earnings for 12 consecutive years, with -$635.4 million as the latest value for Q3 2021.
- On a quarterly basis, Retained Earnings fell 7.81% to -$635.4 million in Q3 2021 year-over-year; TTM through Sep 2021 was -$635.4 million, a 7.81% decrease, with the full-year FY2020 number at -$595.6 million, down 4.99% from a year prior.
- Retained Earnings was -$635.4 million for Q3 2021 at GT Biopharma, down from -$629.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$127.0 million in Q1 2017 to a low of -$635.4 million in Q3 2021.
- A 5-year average of -$461.9 million and a median of -$550.9 million in 2019 define the central range for Retained Earnings.
- Peak YoY movement for Retained Earnings: tumbled 122.41% in 2018, then dropped 4.15% in 2020.
- GT Biopharma's Retained Earnings stood at -$269.5 million in 2017, then tumbled by 94.6% to -$524.5 million in 2018, then decreased by 8.18% to -$567.3 million in 2019, then fell by 4.99% to -$595.6 million in 2020, then fell by 6.68% to -$635.4 million in 2021.
- Per Business Quant, the three most recent readings for GTBP's Retained Earnings are -$635.4 million (Q3 2021), -$629.9 million (Q2 2021), and -$625.1 million (Q1 2021).